Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell

This article was originally published in The Pink Sheet Daily

Executive Summary

Crucell would fit Wyeth’s ongoing effort to extend geographic base for vaccines and provide new candidates and technologies to provide depth to the company’s vaccine R&D effort.

You may also be interested in...



Emilio Emini Is The Key To Wyeth Vaccines

In touting the $68 billion proposed deal for Wyeth, Pfizer CEO Jeff Kindler repeatedly cited Wyeth's vaccine business as a key part of the deal. But what exactly will Pfizer get after scooping up this unit? Two crucial assets - one is a product and the other is a person

Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals

"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth

Emilio Emini Is The Key To Wyeth Vaccines

In touting the $68 billion proposed deal for Wyeth, Pfizer CEO Jeff Kindler repeatedly cited Wyeth's vaccine business as a key part of the deal. But what exactly will Pfizer get after scooping up this unit? Two crucial assets - one is a product and the other is a person

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel